Citadel Advisors
BBIO icon

Citadel Advisors’s BridgeBio Pharma BBIO Stock Holding History

Citadel Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Sell
161,600
-285,900
-64% -$20.7M ﹤0.01% 3005
2025
Q4 		$34.2M Buy
447,500
+170,200
+61% +$11.2M 0.01% 1771
2025
Q3 		$14.4M Buy
277,300
+106,600
+62% +$5.2M ﹤0.01% 2745
2025
Q2 		$7.37M Sell
170,700
-86,200
-34% -$3.14M ﹤0.01% 3475
2025
Q1 		$8.88M Sell
256,900
-126,300
-33% -$4.26M ﹤0.01% 3015
2024
Q4 		$10.5M Buy
383,200
+151,700
+66% +$3.92M ﹤0.01% 2924
2024
Q3 		$5.89M Sell
231,500
-81,500
-26% -$2.14M ﹤0.01% 3687
2024
Q2 		$7.93M Sell
313,000
-39,800
-11% -$1.09M ﹤0.01% 3078
2024
Q1 		$10.9M Buy
352,800
+30,400
+9% +$1.03M ﹤0.01% 2834
2023
Q4 		$13M Sell
322,400
-3,600
-1% -$108K ﹤0.01% 2507
2023
Q3 		$8.6M Sell
326,000
-222,300
-41% -$6.31M ﹤0.01% 2878
2023
Q2 		$9.43M Buy
548,300
+310,300
+130% +$4.67M ﹤0.01% 2755
2023
Q1 		$3.95M Buy
238,000
+177,200
+291% +$2.07M ﹤0.01% 4185
2022
Q4 		$463K Buy
60,800
+30,800
+103% +$295K ﹤0.01% 8400
2022
Q3 		$298K Sell
30,000
-21,700
-42% -$225K ﹤0.01% 9597
2022
Q2 		$469K Sell
51,700
-36,200
-41% -$303K ﹤0.01% 8779
2022
Q1 		$892K Sell
87,900
-438,200
-83% -$4.5M ﹤0.01% 7970
2021
Q4 		$8.78M Buy
526,100
+483,700
+1,141% +$20.5M ﹤0.01% 3286
2021
Q3 		$1.99M Buy
42,400
+24,100
+132% +$1.29M ﹤0.01% 6353
2021
Q2 		$1.12M Sell
18,300
-5,300
-22% -$303K ﹤0.01% 8077
2021
Q1 		$1.45M Sell
23,600
-38,700
-62% -$2.53M ﹤0.01% 7181
2020
Q4 		$4.43M Buy
62,300
+54,600
+709% +$2.63M ﹤0.01% 3879
2020
Q3 		$289K Sell
7,700
-13,400
-64% -$422K ﹤0.01% 8196
2020
Q2 		$688K Sell
21,100
-12,700
-38% -$387K ﹤0.01% 6503
2020
Q1 		$980K Buy
+33,800
New +$1.05M ﹤0.01% 5369

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's BBIO Position: Q1 2026 in Review

Citadel Advisors increased its BridgeBio Pharma (BBIO) stake by 355% in Q1 2026, buying an estimated $179M and bringing the position to 3,173,940 shares worth $236M. The position accounts for 0.04% of the portfolio, ranked #387.

Citadel Advisors first reported a position in BBIO in Q2 2019 and has held it in 24 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Citadel Advisors held 3,173,940 shares of BridgeBio Pharma worth $236M as of Q1 2026.
  • Citadel Advisors bought 2,475,758 BridgeBio Pharma shares in Q1 2026, an estimated $179M.
  • BridgeBio Pharma made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #387 holding.
  • Citadel Advisors first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 24 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.